Has Tibor Toplenszky, MD received payments from drug or device companies?

Yes. Drug and device makers reported $1,622 in general payments to Tibor Toplenszky, MD across 68 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Tibor Toplenszky, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Tibor Toplenszky, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Tibor Toplenszky, MD

Internal Medicine · Sparks, NVNPI 1427022979

Payments from drug & device makers

$1,622in general payments, 2019–2025

Across 68 payments — averaging $23.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

GSK$227
AstraZeneca$220
Johnson & Johnson$144
Astellas Pharma US Inc$125
Lilly USA, LLC$110
Pfizer$101
plus $695 from 21 others

What the payments were for

Food & beverage$1,622100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
GSK	5	$227
AstraZeneca	9	$220
Johnson & Johnson	3	$144
Astellas Pharma US Inc	5	$125
Lilly USA, LLC	5	$110
Pfizer	6	$101
Boehringer Ingelheim	5	$84
Novo Nordisk	5	$73
Si-bone, Inc.	1	$72
Boston Scientific	2	$70
Amgen	2	$49
Merck	3	$49
Supernus Pharmaceuticals, Inc.	1	$32
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)	2	$31
Biohaven Pharmaceuticals, Inc.	2	$28
Collegium Pharmaceutical, Inc.	1	$21
Edwards Lifesciences	1	$21
E.r. Squibb & Sons, L.L.C.	1	$21
Verity Pharmaceuticals Inc.	1	$18
Kowa Pharmaceuticals America, Inc.	1	$18
Tactile Systems Technology Inc	1	$18
Biohaven Pharmaceutical Holding Company Ltd.	1	$16
Takeda Pharmaceuticals U.S.A., Inc.	1	$16
Medtronic	1	$15
Vanda Pharmaceuticals Inc.	1	$14
Avanir Pharmaceuticals, Inc.	1	$14
Eisai Inc.	1	$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

INVOKANA$104

How this compares

$1,622 in reported general payments places this provider in the 80th percentile of 1,071 internal medicine providers in Nevada.

See all internal medicine providers in Nevada →

Medicare billing

Part B allowed, 2024

$13,907

Medicare patients

102

Services billed

169

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Albuterol Sulfate HfaAlbuterol Sulfate	36	$782
Cefdinir	17	$389
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst	31	$289
Ofloxacin	13	$284
Doxycycline Hyclate	31	$265
Methylprednisolone	20	$158
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav	21	$152
Cephalexin	26	$143
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim	23	$69
Azithromycin	12	$43

Paid to pharmacies, not to this prescriber.

Other internal medicine in Sparks

Darin BrimhallLas Vegas$39.7M
Alton WaltersLas Vegas$8.9M
Michael JacobsLas Vegas$8.1M
Nirupa PaulrajLas Vegas$5.8M
Atoya AdamsLas Vegas$5.4M
Roger EstevezLas Vegas$3.7M
Syed PervaizLas Vegas$3.1M
Marigene Salazar SharmaHenderson$2.5M
Mavis MatsumotoHenderson$1.8M
Vrijendra HoonLas Vegas$1.8M

See the full list for Nevada →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →